Stock Track | Kodiak Sciences Soars 5% as Barclays Raises Target Price by 75%

Stock Track

Aug 16, 2025

Shares of Kodiak Sciences Inc. (KOD) surged 5.08% during Friday's trading session following a significant target price upgrade from Barclays. The investment bank raised its price target for the biopharmaceutical company to $7 from $4, representing a substantial 75% increase in their valuation outlook.

The positive adjustment in Barclays' assessment appears to have sparked investor optimism, driving the stock's impressive intraday rally. This upward revision suggests that the bank's analysts have become more bullish on Kodiak Sciences' prospects, potentially due to developments in the company's drug pipeline or improved market conditions for the biotech sector.

Investors and market watchers will be keeping a close eye on Kodiak Sciences in the coming days, as the company is scheduled to report its third-quarter earnings on Monday. The upcoming financial results may provide further insight into the company's performance and could potentially validate or challenge Barclays' optimistic stance on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1165897864"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165897864\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165897864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-16 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165897864","market":"nz","top_or_hot":-1,"title":"Stock Track | Kodiak Sciences Soars 5% as Barclays Raises Target Price by 75%","media":"Stock Track","content":"<p>Shares of Kodiak Sciences Inc. (KOD) surged 5.08% during Friday's trading session following a significant target price upgrade from Barclays. The investment bank raised its price target for the biopharmaceutical company to $7 from $4, representing a substantial 75% increase in their valuation outlook.</p>\n\n<p>The positive adjustment in Barclays' assessment appears to have sparked investor optimism, driving the stock's impressive intraday rally. This upward revision suggests that the bank's analysts have become more bullish on Kodiak Sciences' prospects, potentially due to developments in the company's drug pipeline or improved market conditions for the biotech sector.</p>\n\n<p>Investors and market watchers will be keeping a close eye on Kodiak Sciences in the coming days, as the company is scheduled to report its third-quarter earnings on Monday. The upcoming financial results may provide further insight into the company's performance and could potentially validate or challenge Barclays' optimistic stance on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kodiak Sciences Soars 5% as Barclays Raises Target Price by 75%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kodiak Sciences Soars 5% as Barclays Raises Target Price by 75%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-16 00:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Kodiak Sciences Inc. (KOD) surged 5.08% during Friday's trading session following a significant target price upgrade from Barclays. The investment bank raised its price target for the biopharmaceutical company to $7 from $4, representing a substantial 75% increase in their valuation outlook.</p>\n\n<p>The positive adjustment in Barclays' assessment appears to have sparked investor optimism, driving the stock's impressive intraday rally. This upward revision suggests that the bank's analysts have become more bullish on Kodiak Sciences' prospects, potentially due to developments in the company's drug pipeline or improved market conditions for the biotech sector.</p>\n\n<p>Investors and market watchers will be keeping a close eye on Kodiak Sciences in the coming days, as the company is scheduled to report its third-quarter earnings on Monday. The upcoming financial results may provide further insight into the company's performance and could potentially validate or challenge Barclays' optimistic stance on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"","article_id":"1165897864","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165897864","pubTimestamp":1755275442,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Kodiak Sciences Inc. (KOD) surged 5.08% during Friday's trading session following a significant target price upgrade from Barclays. The investment bank raised its price target for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc."},"translate_title":"个股追踪|Kodiak Sciences大涨5%巴克莱上调目标价75%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":1},"content_text":"Shares of Kodiak Sciences Inc. (KOD) surged 5.08% during Friday's trading session following a significant target price upgrade from Barclays. The investment bank raised its price target for the biopharmaceutical company to $7 from $4, representing a substantial 75% increase in their valuation outlook.\nThe positive adjustment in Barclays' assessment appears to have sparked investor optimism, driving the stock's impressive intraday rally. This upward revision suggests that the bank's analysts have become more bullish on Kodiak Sciences' prospects, potentially due to developments in the company's drug pipeline or improved market conditions for the biotech sector.\nInvestors and market watchers will be keeping a close eye on Kodiak Sciences in the coming days, as the company is scheduled to report its third-quarter earnings on Monday. The upcoming financial results may provide further insight into the company's performance and could potentially validate or challenge Barclays' optimistic stance on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}